Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels

RDUS
Radius Recycling, Inc. Class A Common Stock
stock NASDAQ

Inactive
Jul 10, 2025
30.00USD+0.033%(+0.01)1,720,208
Pre-market
0.00USD-100.000%(-29.99)0
After-hours
0.00USD0.000%(0.00)0
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 20, 2022
07:50AM EST  Radius Pharmaceuticals Filed U.S. Patent Application #20220016052 'METHODS FOR TREATING CANCER IN MODELS HARBORING ESR1 MUTATIONS'   Benzinga
Jan 13, 2022
11:48AM EST  Radius Health Says Fires ~20% Of Non-Sales Personnel   Benzinga
09:00AM EST  -- Completion of three pivotal trials in 2021 enables restructuring of the operating infrastructure -- Non-Sales headcount reduced by approximately 20% -- Reductions focused on areas that supported abaloparatide clinical and regulatory activities -- Company to provide Q4 & FY 2021 results and 2022 outlook during earnings on February 24   GlobeNewswire Inc
Dec 23, 2021
10:41AM EST  FDA Approves Update On Radius Health's Tymlos label   Benzinga
08:31AM EST  Radius Health Offers Update On TYMLOS Label: 'FDA approved the removal of the boxed warning from the TYMLOS label, effective December 22, 2021'   Benzinga
08:30AM EST  -- FDA approved the removal of the boxed warning from the TYMLOS label, effective December 22, 2021 -- The boxed warning had referred to the potential risk of osteosarcoma -- Action follows review of long-term post-marketing data for TYMLOS and PTH class of drugs   GlobeNewswire Inc
Dec 20, 2021
08:32AM EST  Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital cell biology, today announced the appointment of Jessica Hopfield, Ph.D. to the Berkeley Lights Board of Directors as an independent director, effective December 15, 2021.   GlobeNewswire Inc
Dec 16, 2021
05:47AM EST  Radius Health 10%+ Owner David Efraim Rosen Reported Purchase of 462,238 @ Avg Price of $6.90/Share in Form 4 Filing on Wednesday   Benzinga
Dec 10, 2021
12:41PM EST  Benzinga's Top Ratings Upgrades, Downgrades For December 10, 2021   Benzinga
08:15AM EST  Morgan Stanley Downgrades Radius Health to Underweight, Lowers Price Target to $7   Benzinga
07:51AM EST  10 Biggest Price Target Changes For Friday   Benzinga
05:11AM EST  Goldman Sachs Downgrades Radius Health to Neutral, Lowers Price Target to $12   Benzinga
Dec 9, 2021
09:45PM EST  SVB Leerink Maintains Market Perform on Radius Health, Lowers Price Target to $20   Benzinga
09:45PM EST  HC Wainwright & Co. Maintains Neutral on Radius Health, Lowers Price Target to $10   Benzinga
09:38PM EST  Mid-Afternoon Market Update: Nasdaq Rises 70 Points; Stitch Fix Shares Slide   Benzinga
Dec 8, 2021
12:08PM EST  Mid-Day Market Update: Photronics Rises Following Upbeat Q4 Results; Radius Health Shares Slide   Benzinga
10:20AM EST  Radius Health Highlights EMERALD Trial Results For Elacestrant Presented At San Antonio Breast Cancer Symposium: Trial Met Both Primary Endpoints   Benzinga
10:16AM EST  Mid-Morning Market Update: Markets Mixed; United Natural Foods Beats Q1 Views   Benzinga
10:15AM EST  Positive EMERALD Trial Results for Elacestrant Presented at San   GlobeNewswire Inc
09:04AM EST  Radius Announces wearABLe Trial Evaluating Abaloparatide Transdermal System Did Not Meet Primary Endpoint   Benzinga
09:00AM EST  Radius Announces Results from the wearABLe Trial Evaluating   GlobeNewswire Inc
09:00AM EST  Radius Health, Inc. (Radius or the Company) (NASDAQ: RDUS) announced it will host a conference call today, Wednesday, December 8, 2021, at 4:00 p.m. ET to cover the below:   GlobeNewswire Inc
Nov 11, 2021
08:30AM EST  Radius Health, Inc. (Radius or the Company) (NASDAQ: RDUS) today announced that management will participate in the Stifel 2021 Virtual Healthcare Conference, including a fireside chat at 8:40 a.m. ET on Tuesday, November 16, 2021, followed by investor meetings.   GlobeNewswire Inc
Nov 9, 2021
01:29PM EST  What 5 Analyst Ratings Have To Say About Radius Health   Benzinga
12:03PM EST  SVB Leerink Maintains Market Perform on Radius Health, Raises Price Target to $30   Benzinga
11:27AM EST  HC Wainwright & Co. Maintains Neutral on Radius Health, Lowers Price Target to $23   Benzinga
Nov 8, 2021
08:27AM EST  Radius Health Q3 EPS $(0.32) Misses $(0.24) Estimate, Sales $56.81M Miss $61.27M Estimate   Benzinga
08:00AM EST  Radius Health, Inc.: Third Quarter 2021 Results   GlobeNewswire Inc
05:06AM EST  Earnings Scheduled For November 8, 2021   Benzinga
Nov 5, 2021
11:29AM EDT  Earnings Outlook For Radius Health   Benzinga
Oct 21, 2021
01:15PM EDT  In a release issued under the same headline yesterday, Oct. 20, by Radius Health, Inc. (NASDAQ: RDUS), please note that the dial-in numbers were listed incorrectly. The correct dial-in numbers are (866) 323-7965 for domestic calls and (346) 406-0961 for international calls. The conference ID remains the same,9322858. The corrected release appears below:   GlobeNewswire Inc
12:57PM EDT  Analyst Ratings For Radius Health   Benzinga
12:11PM EDT  SVB Leerink Maintains Market Perform on Radius Health, Raises Price Target to $29   Benzinga
12:11PM EDT  HC Wainwright & Co. Maintains Neutral on Radius Health, Raises Price Target to $26   Benzinga
12:10PM EDT  Mid-Afternoon Market Update: Nasdaq Turns Lower; Sesen Bio Shares Surge   Benzinga
Oct 20, 2021
03:00PM EDT  Radius Health, Inc. (NASDAQ: RDUS) announced today that it will release its third quarter financial results on Monday, November 8, 2021. The Company will host a conference call and live audio webcast at 8:30 a.m. ET to discuss the results and provide a company update.   GlobeNewswire Inc
12:18PM EDT  Mid-Day Market Update: Healthcare Services Drops After Q3 Results; Radius Health Shares Jump   Benzinga
10:32AM EDT  Mid-Morning Market Update: Markets Open Higher; Verizon Posts Upbeat Earnings   Benzinga
08:33AM EDT  Radius Health, Menarini Group Report Phase 3 Topline Results From EMERALD Trial For Elacestrant In Breast Cancer: 'Study met both primary endpoints in patients with ER+/HER2- advanced or mBC'   Benzinga
08:30AM EDT  Menarini Group and Radius Health Announce Positive Phase 3 Topline   GlobeNewswire Inc
Oct 18, 2021
09:11AM EDT  Radius Health Inc. (RDUS) announced positive results from the ATOM Phase 3 Study evaluating TYMLOS or abaloparatide 80mcg subcutaneous (SC) for use in males with osteoporosis. The company remains on track for an sNDA submission in the first quarter of 2022.   RTTNews
08:48AM EDT  Radius Announces ATOM Phase 3 Study Of TYMLOS Met Primary And Secondary Endpoints   Benzinga
08:38AM EDT  Radius Health Announces Positive Topline Results From ATOM Study   RTTNews
08:30AM EDT  Radius Announces Positive Phase 3 Topline Results for   GlobeNewswire Inc
Oct 13, 2021
01:38PM EDT  Morgan Stanley Maintains Equal-Weight on Radius Health, Lowers Price Target to $18   Benzinga
Sep 22, 2021
08:00AM EDT  -- TYMLOS label: significant update to the Mechanism of Action (MOA) section -- Label change aligns with strategic focus on postmenopausal women at high risk of fracture -- Danielle Holtschlag joins as Head of Sales, bringing 20 years of experience to the team -- Added ~3,000 new TYMLOS patients throughout July and August, up 13% year-over-year   GlobeNewswire Inc
Sep 7, 2021
11:30AM EDT  Radius Health Earnings Perspective: Return On Capital Employed   Benzinga
Aug 6, 2021
06:16AM EDT  HC Wainwright & Co. Maintains Neutral on Radius Health, Lowers Price Target to $19   Benzinga
05:54AM EDT  SVB Leerink Maintains Market Perform on Radius Health, Raises Price Target to $26   Benzinga
Aug 5, 2021
07:34AM EDT  Radius Health Q2 EPS $(0.22) Beats $(0.33) Estimate, Sales $51.80M Up From $50.11M YoY   Benzinga
07:00AM EDT  Radius Health, Inc.: Second Quarter and Year-to-Date Results   GlobeNewswire Inc
04:08AM EDT  Earnings Scheduled For August 5, 2021   Benzinga
Jul 27, 2021
11:13AM EDT  CORRECTION: Radius Health Ticker Is 'RDUS'   Benzinga
11:13AM EDT  Radius Health Says Added 5,000+ New TYMLOS Patients In Q2   Benzinga
Jul 23, 2021
11:12AM EDT  CORRECTION: Radius Health Announces Plans for Global Prader-Willi   GlobeNewswire Inc
09:27AM EDT  Radius Health Publishes Study Titled 'RWE Cardiovascular Safety Study of Abaloparatide in Postmenopausal Women' To ClinicalTrials.Gov, Study Not Yet Recruiting   Benzinga
Jul 22, 2021
09:02AM EDT  Radius Health Announces Plans For Global Prader-Willi Syndrome Pivotal Study   Benzinga
Jul 20, 2021
05:11PM EDT  Radius Health, Inc. (Nasdaq: RDUS) announced today that it will release its second quarter financial results on Thursday, August 5, 2021. The Company will host a conference call and live audio webcast at 8:30 a.m. ET that day to discuss the results and provide a company update.   GlobeNewswire Inc
Jun 23, 2021
07:35AM EDT  The Daily Biotech Pulse: Gemini Sinks On Data, Amgen's Migraine Drug Approved In Japan, Liver Congress Gets Underway   Benzinga
Jun 2, 2021
08:16AM EDT  Radius Health Provides Business Update; Says TYMLOS Saw 'Modest Growth'   Benzinga
08:15AM EDT  Radius Health Business Update   GlobeNewswire Inc
May 18, 2021
10:27AM EDT  Morgan Stanley Maintains Equal-Weight on Radius Health, Raises Price Target to $20   Benzinga
May 10, 2021
06:57AM EDT  SVB Leerink Maintains Market Perform on Radius Health, Raises Price Target to $24   Benzinga
May 7, 2021
07:40AM EDT  The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs   Benzinga
06:38AM EDT  Radius Health Q1 EPS $(0.34) Beats $(0.41) Estimate, Sales $56.26M Miss $60.38M Estimate   Benzinga
06:30AM EDT  Radius Health, Inc.: First Quarter 2021 Results   GlobeNewswire Inc
04:12AM EDT  Earnings Scheduled For May 7, 2021   Benzinga
May 6, 2021
10:15AM EDT  Radius Health's Earnings: A Preview   Benzinga
Apr 22, 2021
08:18AM EDT  Radius Health Announces US TYMLOS Patient Growth Increased By 14% QoQ   Benzinga
08:15AM EDT  Radius Health Business Update   GlobeNewswire Inc
Apr 20, 2021
04:30PM EDT  Radius Health (Nasdaq: RDUS) announced today that it will release its first quarter financial results on Friday, May 7, 2021. The Company will host a conference call and live audio webcast at 8:30 a.m. ET that day to discuss the results and provide a company update.   GlobeNewswire Inc
Mar 30, 2021
07:17AM EDT  Radius Global Infrastructure FY20 Sales $20.1M, Up 36% YoY   Benzinga
Mar 25, 2021
07:58AM EDT  The Daily Biotech Pulse: Bristol-Myers Squibb's Skin Cancer Readout, Cellect Strikes Reverse Merger Deal, Lava Therapeutics Makes Nasdaq Debut   Benzinga
Mar 24, 2021
08:59AM EDT  The Daily Biotech Pulse: Dynavax-Clover Start Phase 2/3 Vaccine Study. BrainStorm Reports Positive MS Readout, NeoGenomics Goes Shopping   Benzinga
08:08AM EDT  Radius Health Says Teijin Pharma's Ostabaro Approved For Treatment Of Male And Female OP Patients At High Risk Of Fracture In Japan   Benzinga
08:00AM EDT  Radius Health Provides Update on Abaloparatide   GlobeNewswire Inc
Mar 23, 2021
08:18AM EDT  The Daily Biotech Pulse: FDA Approvals For Merck, Pacira And Zealand, Roche-Regeneron Ace Late-Stage COVID-19 Study, AlloVir Appoints Gilead Virology Chief As CEO   Benzinga
01:31AM EDT  AZN's COVID-19 Jab Shows 79% Efficacy, ZEAL Wins FDA   RTTNews
Mar 22, 2021
07:39AM EDT  Goldman Sachs Assumes Radius Health at Buy, Announces Price Target of $33   Benzinga
Mar 3, 2021
04:23PM EST  Radius Health Eliminates Approximately 2.3M Shares Of Potential Future Dilution Upon Conversion Of Notes   Benzinga
04:22PM EST  Radius Health Announces A $175M Financing Transaction   Benzinga
04:22PM EST  Radius Health Reaffirms FY21 Guidance   Benzinga
04:15PM EST  Radius Health, Inc. Announces $175 Million Financing Transaction   GlobeNewswire Inc
Mar 1, 2021
08:05AM EST  10 Biggest Price Target Changes For Monday   Benzinga
06:39AM EST  SVB Leerink Maintains Market Perform on Radius Health, Raises Price Target to $23   Benzinga
Feb 25, 2021
08:08AM EST  The Daily Biotech Pulse: Merck Goes Shopping, Decision Day For Sarepta, Pfizer, Moderna Unveil Vaccine Strategies For Coronavirus Variants   Benzinga
07:25AM EST  Radius Health Q4 EPS $(0.23) Beats $(0.42) Estimate, Sales $62.78M Beat $59.86M Estimate   Benzinga
07:00AM EST  Radius Health, Inc.: Fourth Quarter and Full Year Results   GlobeNewswire Inc
04:03AM EST  Earnings Scheduled For February 25, 2021   Benzinga
Feb 24, 2021
07:47AM EST  10 Biggest Price Target Changes For Wednesday   Benzinga
06:25AM EST  HC Wainwright & Co. Maintains Neutral on Radius Health, Raises Price Target to $25   Benzinga
Feb 17, 2021
08:30AM EST  Radius Health, Inc. (Nasdaq: RDUS), today announced that it will provide a corporate update at the 10th Annual SVB Leerink Global Healthcare Conference at 10:40 a.m. ET on Thursday, February 25, 2021.   GlobeNewswire Inc
Feb 16, 2021
08:30AM EST  Radius Health(Nasdaq: RDUS) announced today that it will release its fourth quarter financial results onThursday, February 25, 2021. The Company will host a conference call and live audio webcast at8:30 a.m. ETthat day to discuss the results and provide a company update.   GlobeNewswire Inc
Feb 12, 2021
12:35PM EST  Radius Health, Inc. Provides Abaloparatide Business Update (Full Statement)   Benzinga
12:33PM EST  Radius Health, Inc. Provides Abaloparatide Business Update   GlobeNewswire Inc
Feb 10, 2021
07:34AM EST  The Daily Biotech Pulse: Lilly COVID-19 Antibody Cocktail Approved for Emergency Use, Gamida, Genfit Jump On Data, 2 IPOs   Benzinga
Feb 9, 2021
08:10AM EST  The Daily Biotech Pulse: Dynavax Poaches GSK Vaccine Exec, KalVista Jumps On Data Readout, Corcept Issues Negative Preannouncement   Benzinga
Jan 8, 2021
07:25AM EST  The Daily Biotech Pulse: Sarepta Gene Therapy Study Readout, Novavax Vaccine Supply Deal, 2 IPOs   Benzinga
Jan 7, 2021
11:56AM EST  Citigroup Maintains Buy on Radius Health, Raises Price Target to $30   Benzinga
08:02AM EST  10 Biggest Price Target Changes For Thursday   Benzinga
06:32AM EST  SVB Leerink Maintains Market Perform on Radius Health, Raises Price Target to $20   Benzinga
Jan 6, 2021
12:00PM EST  Radius Health, Inc.(Nasdaq: RDUS), today announced that Kelly Martin, President and CEO will present a virtual corporate update at the 39thAnnualJ.P. Morgan Healthcare ConferenceonWednesday, January 13 at 9:10 a.m. EST.   GlobeNewswire Inc
06:02AM EST  Radius Health, Inc. Announces Acquisition Of Benuvia Therapeutics Inc.'s RAD011 Cannabidiol Oral Solution For $12.5M With Additional $15M To Be Paid Contingent On The Successful Conclusion Of PWS Development Milestones   Benzinga
06:00AM EST  Radius Health, Inc. Announces Acquisition of Orphan Disease Program   GlobeNewswire Inc
Jan 5, 2021
09:03AM EST  Endo International plc (ENDP) said Tuesday that its subsidiary Endo Ventures Limited has entered into definitive agreements with Radius Health, Inc. (RDUS) to register, commercialize and distribute abaloparatide on an exclusive basis in Canada. Paladin Labs Inc., an operating company of Endo, will be responsible for all commercial activities related to abaloparatide.   RTTNews
08:39AM EST  Endo Ventures Enters Licensing Agreement For Paladin Labs To Commercialize Abaloparatide In Canada   RTTNews
08:37AM EST  Endo Announces Licensing Agreement for Paladin Labs Inc. to Commercialize   PR Newswire
08:23AM EST  Radius Health Enters Definitive Agreements With Endo Ventures For Abaloparatide   RTTNews
08:22AM EST  Radius Health Announces Commercial Agreement With Paladin Labs For Abaloparatide in Canada   Benzinga
08:15AM EST  -- Agreement incorporates TYMLOS and abaloparatide-TD -- Consideration includes upfront payment, milestones based on clinical, regulatory and commercial progression, as well as royalties -- Key first step in expanding the global footprint for the abaloparatide asset beyond the U.S. and Japan; a key focus area for the company for 2021   GlobeNewswire Inc
Jan 4, 2021
04:30PM EST  Radius Health, Inc.(Radius or the Company) (Nasdaq: RDUS) announced today that Machelle Sanders and Dr. Andrew C. von Eschenbach have joined the Companys board of directors. Ms. Sanders and Dr. von Eschenbach will fill vacancies created by the departures of Jessica Hopfield, Ph.D. and Tony Rosenberg, who stepped down from the board on December 31, 2020 after years of service.   GlobeNewswire Inc
Dec 15, 2020
09:13AM EST  Radius Health Offers Update On Commercial Progress, Research, Talent   Benzinga
09:00AM EST  -- Continued growth in net new patients for the month of November 2020 -- Company is on-track for record quarter in net revenue for TYMLOS-SC -- Research Agreement reached with MGH in October 2020 -- Hired Head of Clinical Development for the abaloparatide molecule   GlobeNewswire Inc
Nov 5, 2020
08:01AM EST  Radius Health Q3 Adj. EPS $0.15 Beats $(0.21) Estimate, Sales $77.83M Miss $78.38M Estimate   Benzinga
07:54AM EST  The Daily Biotech Pulse: Bluebird Bio Plunges On Regulatory Filing Delay, Synlogic Soars On Study Initiation, European Label Expansion For Vertex, Merck Goes Shopping   Benzinga
04:34AM EST  Earnings Scheduled For November 5, 2020   Benzinga
Nov 2, 2020
08:59AM EST  Morgan Stanley Maintains Equal-Weight on Rocket Companies, Lowers Price Target to $23   Benzinga
Nov 1, 2020
09:40AM EST  The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings   Benzinga
Oct 22, 2020
08:04AM EDT  10 Biggest Price Target Changes For Thursday   Benzinga
06:45AM EDT  HC Wainwright & Co. Maintains Neutral on Radius Health, Lowers Price Target to $22   Benzinga
Oct 21, 2020
08:15AM EDT  Radius Health, Inc.: Progress Since May 2020   GlobeNewswire Inc
Oct 20, 2020
04:15PM EDT  Radius Health (Nasdaq: RDUS) announced today that it will release its third quarter financial results on Thursday, November 5, 2020. The Company will host a conference call and live audio webcast at 8:30 a.m. ET that day to discuss the results and provide a company update.   GlobeNewswire Inc
Oct 6, 2020
04:30PM EDT  Radius Health, Inc.(Radius or the Company) (Nasdaq: RDUS) today announced that Peter A. Schwartzman is joining the company as Vice President in the newly formed Capital, Strategy and Transactions (CST) Group. Peter, as part of the group, will report to Kelly Martin, CEO of Radius.   GlobeNewswire Inc
Oct 1, 2020
09:03AM EDT  Radius Health Reports Will Divest Its RAD 140 Program To Ellipses Pharma, No Terms Disclosed   Benzinga
08:45AM EDT  -- Business development step enables molecule to move forward -- Program progression will be at no financial risk to Radius -- Reinforces Radiusfocus on execution of core business   GlobeNewswire Inc
Sep 25, 2020
06:06AM EDT  Radius Health Reports Target Enrollment Milestone Reached For Phase 3 EMERALD Study Of Elacestrant   Benzinga
05:55AM EDT  Radius Health : Target Enrollment Milestone Reached In Phase 3 EMERALD Study   RTTNews
05:52AM EDT  Radius Health & Menarini Group Provide Elacestrant Update   PR Newswire
Sep 24, 2020
04:25PM EDT  Radius Health & Menarini Group Announces The Its EMERALD Phase 3 Study Reached Its Target Enrollment Milestone And The Life Cycle Planning Is Advancing In Parallel With The Current Phase 3 Monotherapy Program   Benzinga
04:15PM EDT  -- Target enrollment milestone reached in the Phase 3 EMERALD study -- Life cycle planning advancing in parallel with current Phase 3 monotherapy program   GlobeNewswire Inc
08:22AM EDT  Radius Health: Jose Carmona To Be Stepping Down As CFO   RTTNews
08:15AM EDT  -- Organizational Changewithin Finance Function -- Creates Capital, Strategy &Transactions Group   GlobeNewswire Inc
Sep 9, 2020
07:45AM EDT  Radius Health, Inc. (Radius or the Company) (Nasdaq: RDUS) today announced data presentations on abaloparatide-SC at the upcoming American Society for Bone and Mineral Research (ASBMR) 2020 Annual Virtual Meeting which will take place between September 11-15.   GlobeNewswire Inc
Sep 8, 2020
08:16AM EDT  Radius Health Announces Enrollment Completed For Phase 3 wearABLe trial   Benzinga
08:00AM EDT  -- Innovative transdermal technology enables delivery of abaloparatide molecule a peptide - across the skin -- Trial success followed by regulatory approval would provide a completely unique drug administration option for postmenopausal women with osteoporosis. -- wearABLe progress follows recent male study enrollment completion   GlobeNewswire Inc
Sep 2, 2020
04:15PM EDT  Radius Health, Inc.(Nasdaq: RDUS) today announced its participation in the following conferences inSeptember 2020.   GlobeNewswire Inc
Aug 25, 2020
09:16AM EDT  Radius Health Says TYMLOS Patent Extended To 2031; Says Enrollment Completed For ATOM Phase 3 Study Assessing The Efficacy, Safety Of Abaloparatide-SC In Males With Osteoporosis   Benzinga
09:12AM EDT  Radius Health Announces Business Update Including Extension Of Patent For TYMLOS   RTTNews
09:00AM EDT  -- TYMLOS patent extended to 2031, adding approximately 3 years to the TYMLOS-SC patent life -- Enrollment completed for ATOM Phase 3 study assessing the efficacy and safety of abaloparatide-SC in males with osteoporosis   GlobeNewswire Inc
07:53AM EDT  Morgan Stanley Maintains Equal-Weight on Radius Health, Lowers Price Target to $19   Benzinga
Aug 11, 2020
07:44AM EDT  Citigroup Maintains Buy on Radius Health, Lowers Price Target to $25   Benzinga
Aug 10, 2020
08:44AM EDT  Radius Health: Q2 Earnings Insights   Benzinga
08:19AM EDT  Radius Health Appoints Sean Murphy To Its Board   RTTNews
08:18AM EDT  Radius Health Q2 Net Loss $43.9 Mln Or $0.95/Shr Vs Loss $35.5 Mln Or $0.77/Shr Last Year   RTTNews
08:15AM EDT  Radius Health, Inc. (Radius or the Company) (Nasdaq: RDUS) today announced the appointment of Sean Murphy to its Board of Directors with immediate effect.   GlobeNewswire Inc
08:15AM EDT  TYMLOS U.S. net sales of $50 million, with 22% year over year growth   GlobeNewswire Inc
08:09AM EDT  Radius Health Q2 EPS $(0.95) Misses $(0.74) Estimate, Sales $50.11M Beat $48.40M Estimate   Benzinga
04:10AM EDT  Earnings Scheduled For August 10, 2020   Benzinga
Jul 30, 2020
05:07PM EDT  Guardant Health Reports Collaboration With Radius Health To Develop Liquid Biopsy Companion Diagnostic For Elacestrant   Benzinga
Jul 27, 2020
04:15PM EDT  Radius Health (Nasdaq: RDUS) announced today that it will release its second quarter financial results on Monday, August 10, 2020. The Company will host a conference call and live audio webcast at 8:30 a.m. ET that day to discuss the results and provide a company update.   GlobeNewswire Inc
Jul 24, 2020
04:53AM EDT  SVB Leerink Maintains Market Perform on Radius Health, Raises Price Target to $18   Benzinga
Jul 23, 2020
04:20PM EDT  Radius Health Reports Global License Deal For Development, Commercialization Of Elacestrant With Menarini Group, Co. Will Receive $30M Upfront Payment, Up To $320M In Added Milestone Payments   Benzinga
04:15PM EDT  Menarini Group and Radius Health Announce Global License   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC